BOSTON and ATLANTA, July 17,
2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc.
(Nasdaq: IKT) (Inhibikase or Company), a clinical-stage
pharmaceutical company developing protein kinase inhibitor
therapeutics to modify the course of Parkinson's disease ("PD"),
Parkinson's-related disorders and other diseases of the Abelson
Tyrosine Kinases, today announced that it received written notice
on July 17, 2023 from the Listing
Qualifications Staff of The Nasdaq Stock Market, LLC (Nasdaq)
indicating that Inhibikase Therapeutics has regained full
compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule
5550(a)(2), and that Inhibikase is in compliance with all
applicable listing standards.
About Inhibikase (www.inhibikase.com)
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is
a clinical-stage pharmaceutical company developing therapeutics for
Parkinson's disease and related disorders. Inhibikase's
multi-therapeutic pipeline has a primary focus on neurodegeneration
and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl)
inhibitor, targets the treatment of Parkinson's disease inside and
outside the brain as well as other diseases that arise from Ableson
Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing
Parkinson's-related disorders of the brain and GI tract, orphan
indications related to Parkinson's disease such as Multiple System
Atrophy, and drug delivery technologies for kinase inhibitors such
as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate
that the Company believes will provide a better patient experience
with fewer on-dosing side-effects. The Company's RAMP™
medicinal chemistry program has identified a number of follow-on
compounds to IkT-148009 to be potentially applied to other
cognitive and motor function diseases of the brain. Inhibikase is
headquartered in Atlanta, Georgia
with an office in Lexington,
Massachusetts.
Social Media Disclaimer
Investors and others should
note that we announce material financial information to our
investors using our investor relations website, press releases, SEC
filings and public conference calls and webcasts. The Company
intends to also
use Twitter, Facebook, LinkedIn and YouTube as
a means of disclosing information about the Company, its services
and other matters and for complying with its disclosure obligations
under Regulation FD.
Forward-Looking Statements
This press release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
terminology such as "believes," "expects," "may," "will," "should,"
"anticipates," "plans," or similar expressions or the negative of
these terms and similar expressions are intended to identify
forward-looking statements. These forward-looking statements are
based on Inhibikase's current expectations and assumptions. Such
statements are subject to certain risks and uncertainties, which
could cause Inhibikase's actual results to differ materially from
those anticipated by the forward-looking statements, including our
ability to successfully conduct clinical trials and that results in
our animal studies may not be replicated in humans. Important
factors that could cause actual results to differ materially from
those in the forward-looking statements include factors that are
delineated in our periodic reports on Form 10-K and Form 10-Q that
we file with the U.S. Securities and Exchange Commission. Any
forward-looking statement in this release speaks only as of the
date of this release. Inhibikase undertakes no obligation to
publicly update or revise any forward-looking statement, whether as
a result of new information, future developments or otherwise,
except as may be required by any applicable securities laws.
Contacts:
Company Contact:
Milton H.
Werner, PhD
President & CEO
678-392-3419
info@inhibikase.com
Investor Relations:
Alex
Lobo
SternIR, Inc.
alex.lobo@sternir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/inhibikase-therapeutics-regains-compliance-with-nasdaq-listing-requirements-301878618.html
SOURCE Inhibikase Therapeutics, Inc.